SEI Investments
FDMT icon

SEI Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

SEI Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
16,664
+3,802
+30% +$37K ﹤0.01% 3007
2026
Q1 		$120K Buy
12,862
+1,050
+9% +$9.14K ﹤0.01% 3068
2025
Q4 		$88.6K Buy
11,812
+139
+1% +$1.41K ﹤0.01% 3028
2025
Q3 		$101K Sell
11,673
-16,862
-59% -$101K ﹤0.01% 2714
2025
Q2 		$106K Buy
28,535
+103
+0.4% +$362 ﹤0.01% 2682
2025
Q1 		$91.8K Buy
+28,432
New +$134K ﹤0.01% 2612
2024
Q2 		– Sell
-15,818
Closed -$504K – 2673
2024
Q1 		$504K Buy
+15,818
New +$404K ﹤0.01% 2113

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

SEI Investments's FDMT Position: Q2 2026 in Review

SEI Investments increased its 4D Molecular Therapeutics (FDMT) stake by 30% in Q2 2026, buying an estimated $37K and bringing the position to 16,664 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

SEI Investments first reported a position in FDMT in Q1 2024 and has held it in 7 quarters since. The position peaked at $504K in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • SEI Investments held 16,664 shares of 4D Molecular Therapeutics worth $222K as of Q2 2026.
  • SEI Investments bought 3,802 4D Molecular Therapeutics shares in Q2 2026, an estimated $37K.
  • 4D Molecular Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3007 holding.
  • SEI Investments first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • SEI Investments's 4D Molecular Therapeutics position peaked at $504K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.